Growth hormone and aging cardiomyocytes

Clicks: 10
ID: 331636
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #128 of 140 articles by views in cardiovascular research

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 140 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract The age-related decline in growth hormone (GH) secretion, termed the somatopause, parallels the structural and functional deterioration of the aging heart. How this endocrine withdrawal translates into myocardial failure at the molecular level remains incompletely mapped. GH/insulin-like growth factor 1 (IGF-1) signaling acts via PI3K/Akt/mTOR and Ras/MAPK/c-Myc cascades on four processes central to cardiac aging: Akt-dependent nuclear retention of telomerase reverse transcriptase (TERT), established primarily in non-cardiomyocyte models; PGC-1α-driven mitochondrial biogenesis; suppression of the p53/p16INK4a senescence program; and metabolic-epigenetic regulation of cell-cycle competence via α-ketoglutarate/KDM5 and JMJD3 chromatin gating. In mouse cardiomyocytes, positive transcription elongation factor b (P-TEFb) is rate-limiting for Myc-driven proliferation, plausibly explaining why adult cardiomyocytes retain latent cell-cycle machinery yet rarely divide. A candidate GHRHR-HIF-1α axis, presently supported by preprint evidence, is examined as an emerging hypothesis for cell-type-selective cardioprotection independent of systemic GH. We integrate these strands along a single tractable axis: IGF-1/Akt/TERT/p53/PGC-1α with metabolic-epigenetic modulation. The 2025 Marra trial (NCT03775993; 64 randomized, 45 completers; surrogate and functional endpoints not powered for clinical events) reports that physiological GH restoration improves peak VO2 (+3.1 vs −1.8 mL/kg/min, P<0.01), NYHA class, and quality of life in heart failure with confirmed GH deficiency. A meta-analysis of 25 studies quantifies the U-shaped IGF-1-heart failure relationship, with the HF-versus-control IGF-1 difference derived from six of those studies. Plasma proteomic organ-aging signatures show accelerated cardiac aging is associated with 2.5-fold heart-failure risk. We present a hypothesis-generating framework identifying GH/IGF-1 axis restoration as a candidate determinant of heart-failure progression, warranting event-driven confirmation.
Reference Key
openalex_W7220833724 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Eckhard Udo Alt, Reza Izadpanah
Journal cardiovascular research
Year 2026
DOI
10.1093/cvr/cvag225
URL
https://academic.oup.com/cardiovascres/advance-article-pdf/doi/10.1093/cvr/cvag225/71638930/cvag225.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.